Protective autoantibodies: Role in homeostasis, clinical importance, and therapeutic potential

Arthritis and Rheumatism

Volumn 52, Issue 9, 2005, Pages 2599-2606

  Shoenfeld, Yehuda ^a,c   Toubi, Elias ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b BNAI ZION MEDICAL CENTER   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; DNA ANTIBODY; IMMUNOGLOBULIN; INTERLEUKIN 5; PHOSPHOLIPID ANTIBODY; RHEUMATOID FACTOR;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; DRUG MEGADOSE; HOMEOSTASIS; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; DNA; HOMEOSTASIS; HUMANS; IMMUNITY; IMMUNOGLOBULIN G; MICE;

EID: 25444485683     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21252     Document Type: Review

References (61)

1. Nevo U, Kipnis J, Golding I, Shaked I, Neumann A, Akselrod S, Schwartz M. Autoimmunity as a special case of immunity: aiding to remove threats from within. Trends Mol Med 2003;9:88-93.
2. Schori H, Yoles E, Schwartz M. T-cell-based immunity counteracts the potential toxicity of glutamate in the central nervous system. J Neuroimmunol 2001;119:199-204.
3. Yoles E, Hauben E, Palgi O, Agranov E, Gothilf A, Cohen A, et al. Protective autoimmunity is a physiological response to CNS trauma [published erratum in J Neurosci 2001;21:1A]. J Neurosci 2001;21:3740-8.
4. Kipnis J, Mizrahi T, Yoles E, Ben-Nun A, Schwartz M, Ben-Nur A. Myelin specific Th1 cells are necessary for post-traumatic protective autoimmunity. J Neuroimmunol 2002;130:78-85.
5. Shaked I, Portal Z, Gersner R, Kipnis J, Schwartz M. Early activation of microglia as antigen-presenting cells correlates with T cell-mediated protection and repair of the injured central nervous system. J Neuroimmunol 2004;146:84-93.
6. Schwartz M, Kipnis J. Autoimmunity on alert: naturally occurring regulatory CD4+CD25+ T cells as part of the evolutionary compromise between a "need" and a "risk." Trends Immunol 2002;23:530-4.
7. Shoenfeld Y, Isenberg DA. Natural autoimmunity. In: The mosaic of autoimmunity. Amsterdam: Elsevier; 1989. p. 53-74.
8. Boes M. Role of natural and immune IgM antibodies in immune responses. Mol Immunol 2000;37:1141-9.
9. Stahl D, Sibrowski W. Regulation of the immune response by natural IgM: lessons from warm autoimmune hemolytic anemia. Curr Pharm Des 2003;9:1871-80.
10. Oppezzo P, Dighiero G. Autoantibodies, tolerance and autoimmunity. Pathol Biol (Paris) 2003;51:297-304.
11. Graber P. The "globulines-transporteurs" theory and autosensitization. Med Hypotheses 1975;5:172-5.
12. Hinter H, Romani N, Stanzl U, Grubauer G, Fritsch P, Lawley TJ. Phagocytosis of keratin filament aggregates following opsonization with IgG anti-keratin antibodies. J Invest Dermatol 1987;88:176-82.
13. Boes M, Schmidt T, Linkemann K, Beaudette BC, Marshak-Rothstein A, Chen J. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci U S A 2000;97:1184-9.
14. Varambally S, Bar-Dayan Y, Bayry J, Lacroix-Desmazes S, Horn M, Sorel M, et al. Natural human polyreactive IgM induce apoptosis of lymphoid cell lines and human peripheral blood mononuclear cells. Int Immunol 2004;16:517-24.
15. Melero J, Tarrago D, Nunez-Roldan A, Sanchez B. Human polyreactive IgM monoclonal antibodies with blocking activity against self-reactive IgG. Scand J Immunol 1997;45:393-400.
16. Vakil M, Kearney JF. Functional characterization of monoclonal auto-anti-idiotypic antibodies isolated from the early B cell repertoire of BALB/c mice. Eur J Immunol 1986;16:1151-8.
17. Mockridge CI, Rahman A, Bacham S, Hamblin T, Isenberg DA, Stevenson FK, et al. Common patterns of B cell perturbation and expanded V4-34 immunoglobulin gene usage in autoimmunity and infection. Autoimmunity 2004;37:9-15.
18. Kohler H, Bayry J, Nicoletti A, Kaveri SV. Natural autoantibodies as tools to predict the outcome of immune response? Scand J Immunol 2003;58:285-9.
19. 2 derived from asymmetric murine IgG3 mAb determines the acquisition of precipitating activity. Mol Immunol 1995;32:1123-30.
20. Canellada A, Gentile T, Dokmetjian J, Margni RA. Occurrence properties and function of asymmetric IgG molecules isolated from non-immune sera. Immunol Invest 2002;31:107-20.
21. Margni RA, Malan Borel I. Paradoxical behavior of asymmetric IgG antibodies. Immunol Rev 1998;163:77-87.
22. Hahn BH. Antibodies to DNA. N Engl J Med 1998;338:1359-68.
23. Bootsma H, Spronk PE, Hummel EJ, de Boer G, ter Borg EJ, Limburg PC, et al. Anti-dsDNA antibodies in SLE: detection and clinical relevance of IgM-class antibodies. Scand J Rheumatol 1996;25:352-6.
24. Witte T, Hartung K, Sachse C, Matthias T, Fricke M, Deicher H, et al, and the SLE Study Group. IgM anti-dsDNA antibodies in SLE: negative association with nephritis. Rheumatol Int 1998;18:85-91.
25. Forger F, Matthias T, Oppermann M, Becker H, Helmke K. Clinical significance of anti-ds DNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis. Lupus 2004;13:36-44.
26. Werwitzke S, Trick D, Kamino K, Matthias T, Kniesch K, Schlegelberger B. Treatment of murine SLE with IgM anti-dsDNA autoantibodies: from animal models to human genetics. In: Conrad K, Bachman P, Chan EK, Fritzler MJ, Humbel RL, Shoenfeld Y, editors. Research on the induction and pathogenicity of autoantibodies. Berlin: PABST Science Publ; 2004. p. 107-9.
27. Turner-Stokes L, Jones M, Addison I, Mansell M, Isenberg D. Does rheumatoid factor protect lupus patients from the development of nephritis? Ann Rheum Dis 1989;48:14-6.
28. Tarkowski A, Westberg G. Rheumatoid factor isotypes and renal disease in SLE. Scand J Rheumatol 1987;16:309-12.
29. Bolton WK, Schrock JH, Davis JS IV. Rheumatoid factor inhibition of in vitro binding of IgG complex in the human glomerulus. Arthritis Rheum 1982;25:297-303.
30. Witte T, Hartung K, Sachse C Matthias T, Fricke M, Kalden JR, et al, and the SLE Study Group. Rheumatoid factor in SLE: association with clinical and laboratory parameters. Rheumatol Int 2000;19:107-11.
31. Spadaro A, Riccieri V, Terracina S, Rinaldi T, Taccari E, Zoppini A. Class specific rheumatoid factor and antiphospholipid syndrome in SLE. Lupus 2000;9:56-60.
32. Wildbaum G, Nahir MA, Karin N. Beneficial autoimmunity to proinflammatory mediators restrains the consequences of self-destructive immunity. Immunity 2003;19:679-88.
33. Bagnato F, Clemenzi A, Scagnolari C, Strizzi L, di Pasquale A, Bellomi F, et al. Neutralizing antibodies against endogenous interferon in myasthenia gravis patients. Eur Cytokine Netw 2004;15:24-9.
34. Robey IF, Schluter SF, Akporiaye E, Yocum DE, Marchalonis JJ. Human monoclonal natural autoantibodies against the T-cell receptor inhibit interleukin-2 production in murine T cells. Immunology 2002;105:419-29.
35. Jambou F, Zhang W, Menestrier M, Klingel-Schmitt I, Michel O, Caillat-Zucman S, et al. Circulating regulatory anti-T cell receptor antibodies in patients with myasthenia gravis. J Clin Invest 2003;112:265-74.
36. Palinski W, Horkko S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK, et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice: demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 1996;98:800-14.
37. Shoenfeld Y, Harats D, Wick G, editors. Atherosclerosis and autoimmunity. Amsterdam: Elsevier; 2001. p. 1-370.
38. Khoo JC, Miller E, Pio F, Steinberg D, Witztum JL. Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates. Arterioscler Thromb 1992;12:1258-60.
39. Yonder Thusen JH, Kniper J, van Berkel TJ, Diessen EA. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev 2003;55:133-66.
40. Palinski W, Ord VA, Plump AS, Breslow JL, Steinberg D, Wiztum JL. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis: demonstration of oxidation-specific epitopes in lesion and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb 1994;14:605-16.
41. Shaw PX, Horkko S, Chang MK, Curtiss LK, Palinski W, Silverman GJ, et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest 2000;105:1731-40.
42. George J, Afek A, Gilburd B, Levkovitz H, Shaish A, Goldberg I, et al. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde LDL suppresses early atherogenesis. Atherosclerosis 1998;138:147-52.
43. Fukumoto M, Shoji T, Emoto M, Kawagishi T, Okuno Y, Nishizawa Y. Antibodies against ox-LDL and carotid artery intima-media thickness in a healthy population. Atheroscler Thromb Vasc Biol 2000;20:703-7.
44. Karvonen J, Paivansalo M, Kesaniemi YA, Horkko S. Immunoglobulin M type of autoantibodies to ox-LDL has an inverse relation to carotid artery atherosclerosis. Circulation 2003;108:2107-12.
45. Brizzi P, Tonolo G, Bertrand G, Carusillo F, Severino C, Maioli M, et al. Auto-antibodies against ox-LDL and LDL oxidation status. Clin Chem Lab Med 2004,42:164-70.
46. Shoenfeld Y, Wu R, Dearing L, Matsuura E. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation 2004;110:2552-8.
47. Chang MK, Bergmark C, Laurila A, Horkko S, Han KH, Friedman P, et al. Monoclonal antibodies against oxLDL bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. Proc Natl Acad Sci U S A 1999;96:6353-8.
48. Binder CJ, Hartvigsen K, Chang MK, Miller M, Broide D, Palinski W, et al. IL-5 links adaptive and natural immunity specific for epitopes of oxLDL and protects from atherosclerosis. J Clin Invest 2004;114:427-37.
49. Alving CR, Wassef N. Naturally occurring antibodies to cholesterol: a new theory of LDL cholesterol metabolism. Immunol Today 1999;20:362-6.
50. Sherer Y, Shoenfeld Y. Antiphospholipid antibodies: are they pro-atherogenic or an epiphenomenon of atherosclerosis? Immunobiology 2003;207:13-6.
51. Nicolo D, Goldman BI, Monestier M. Reduction of atherosclerosis in low-density lipoprotein receptor-deficient mice by passive administration of antiphospholipid antibody. Arthritis Rheum 2003;48:2974-8.
52. Nicolo D, Monestier M. Antiphospholipid antibodies and atherosclerosis. Clin Immunol 2004;112:183-9.
53. Lane C, Leitch J, Tan X, Hadjati J, Bramson JL, Wan Y. Vaccination-induced autoimmune vitiligo is a consequence of secondary trauma to the skin. Cancer Res 2004;64:1509-14.
54. Lacroix-Desmazes S, Mouthon L, Spalter SH, Kaveri S, Kazatchkine MD. Immunoglobulins and the regulation of autoimmunity through the immune network [review]. Clin Exp Rheumatol 1996;14 Suppl 1:S9-15.
55. Coggeshall KM. Inhibitory signaling by B cell FcγRIIb. Curr Opin Immunol 1998;10:306-12.
56. Bayry J, Misra N, Latry V, Frost F, Delignat S, Lacroix-Desmazes S, et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases [review]. Transfus Clin Biol 2003;10:165-9.
57. Altznauer F, von Gunter S, Spath P, Simon HU. Concurrent presence of agonistic and antagonistic anti-CD95 auto-Abs in IVIg preparations. J Allergy Clin Immunol 2003;112:1185-90.
58. Levy Y, Sherer Y, Ahmed A, Langevitz P, George J, Fabbrizzi F, et al. A study of 20 SLE patients with IVIG: clinical and serological response. Lupus 1999;8:705-12.
59. Shoenfeld Y, Rauva L, Gilburd B, Kvapil F, Goldberg I, Koplovic J, et al. Efficacy of IVIG affinity-purified anti-dsDNA anti-idiotypic antibodies in the treatment of an experimental murine model of SLE. Int Immunol 2002;14:1303-11.
60. Krause I, Blank M, Levi I, Koike T, Barak V, Shoenfeld Y. Anti-idiotype immunomodulation of experimental antiphospholipid syndrome via effect on Th1/Th2 expression. Clin Exp Immunol 1999;117:190-7.
61. Wu R, Shoenfeld Y, Sherer Y, Patnaik M, Matsuura E, Gilburd B, et al. Anti-idiotypes to oxidized LDL antibodies in intravenous immunoglobulin preparations: possible immunomodulation of atherosclerosis. Autoimmunity 2003;36:91-7.